![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
May 28, 2021
In an annual evaluation, 22 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
May 28, 2021
The EA8185 phase II trial is the first prospective study exclusively for patients with lymph node positive bladder cancer
May 28, 2021
April 27, 2021
With cherry blossoms finished weeks ago, and fragrant magnolia blooms littering paths, Philadelphia is well into spring, and that means it must be time for an ECOG-ACRIN Group Meeting
April 27, 2021
Most of us are virtual meeting pros by now—and though many miss the connection and energy of in-person events, there is something to be said for attending sessions in sweatpants, a favorite coffee mug in hand
April 27, 2021
A Standing Main Member of ECOG-ACRIN since 2005
April 27, 2021
March 31, 2021
March 31, 2021
This phase II study, led by Dr. Ahmad Tarhini, is testing neoadjuvant treatment with pembrolizumab alone versus pembrolizumab and an investigational drug called CMP-001
March 31, 2021
This phase III study, led by Drs. Patrick Forde and Anna Nowak, is evaluating durvalumab immunotherapy during and after standard chemotherapy versus chemotherapy alone
March 31, 2021
The EA9171 phase II trial aims to determine if adding pembrolizumab immunotherapy to standard-of-care TKI therapy helps more patients achieve undetectable minimal residual disease and allows them to discontinue TKI therapy
March 31, 2021
